- Главная
- Разное
- Дизайн
- Бизнес и предпринимательство
- Аналитика
- Образование
- Развлечения
- Красота и здоровье
- Финансы
- Государство
- Путешествия
- Спорт
- Недвижимость
- Армия
- Графика
- Культурология
- Еда и кулинария
- Лингвистика
- Английский язык
- Астрономия
- Алгебра
- Биология
- География
- Детские презентации
- Информатика
- История
- Литература
- Маркетинг
- Математика
- Медицина
- Менеджмент
- Музыка
- МХК
- Немецкий язык
- ОБЖ
- Обществознание
- Окружающий мир
- Педагогика
- Русский язык
- Технология
- Физика
- Философия
- Химия
- Шаблоны, картинки для презентаций
- Экология
- Экономика
- Юриспруденция
3 Stocks Crushed by the Market This Week презентация
Содержание
- 1. 3 Stocks Crushed by the Market This Week
- 2. Health care saw plenty of huge winners
- 3. The biopharmaceutical company’s shares plunged 35% for
- 4. A blog posted on an investment community
- 5. Shares of the biopharmaceutical firm dropped 18%
- 6. Emails were made public showing that Intercept
- 7. The stock of the biotech fell nearly
- 8. Pharmacyclics announced on Friday that Paula Boultbee,
- 9. Any of this week’s big losers could
- 10. Find out which stock The Motley Fool’s
Health care saw plenty of huge winners this week – but some stocks also got crushed by the market. Here are three of the biggest losers. 1 2 3
Слайд 2Health care saw plenty of huge winners this week – but
some stocks also got crushed by the market. Here are three of the biggest losers.
1
2
3
Слайд 3The biopharmaceutical company’s shares plunged 35% for the week.
Provectus Biopharmaceuticals
(NYSEMKT:PVCT)
Source: Yahoo! Finance
Слайд 4A blog posted on an investment community website alleged that Provectus
appeared to have failed to win Breakthrough Therapy Designation for cancer drug PV-10
Provectus responded publicly on Wednesday, stating that the FDA had not reported any status as of yet
On Friday, however, the company announced that the FDA had indeed denied Breakthrough Therapy Designation for PV-10
Provectus stated that it remains committed to bringing the drug to market
Provectus responded publicly on Wednesday, stating that the FDA had not reported any status as of yet
On Friday, however, the company announced that the FDA had indeed denied Breakthrough Therapy Designation for PV-10
Provectus stated that it remains committed to bringing the drug to market
Why Provectus shares were pummeled
Слайд 5Shares of the biopharmaceutical firm dropped 18% this week.
Intercept Pharmaceuticals
(Nasdaq:ICPT)
Source: Yahoo! Finance
Слайд 6Emails were made public showing that Intercept didn’t disclose lipid abnormalities
related to use of its liver disease drug obeticholic acid, or OCA, when it announced an early stop to a clinical trial in January
Intercept’s stock shot up over 280% after the clinical study ended early, having met its primary endpoint
The company announced in March that there were 10 cardiovascular events in a study of OCA, but the number was not statistically significantly different than the placebo arm of the study
Intercept’s stock shot up over 280% after the clinical study ended early, having met its primary endpoint
The company announced in March that there were 10 cardiovascular events in a study of OCA, but the number was not statistically significantly different than the placebo arm of the study
Why Intercept’s stock imploded
Слайд 7The stock of the biotech fell nearly 11% this week.
Pharmacyclics
(NASDAQ:PCYC)
Source: Yahoo! Finance
Слайд 8Pharmacyclics announced on Friday that Paula Boultbee, Executive VP of Sales
& Marketing, resigned
Boultbee had worked with the company’s collaboration partner Janssen, a unit of Johnson & Johnson, on commercialization of mantle cell lymphoma and chronic lymphocytic leukemia drug Imbruvica
This news followed another staff change earlier in the week, with Greg Wade being named as Executive VP of Business Development
Boultbee had worked with the company’s collaboration partner Janssen, a unit of Johnson & Johnson, on commercialization of mantle cell lymphoma and chronic lymphocytic leukemia drug Imbruvica
This news followed another staff change earlier in the week, with Greg Wade being named as Executive VP of Business Development
Why Pharmacyclics shares faltered
Слайд 9Any of this week’s big losers could mount a comeback
Pharmacyclics seems
to be the best bet for rebounding
This week’s sell-off on news of the sales VP resigning seems overdone
Despite potential competition from other drugs in development, Imbruvica still has solid prospects
Barring any damaging revelations about Boultbee’s exit, Pharmacyclics shares should regain steam
This week’s sell-off on news of the sales VP resigning seems overdone
Despite potential competition from other drugs in development, Imbruvica still has solid prospects
Barring any damaging revelations about Boultbee’s exit, Pharmacyclics shares should regain steam
Best shot at bouncing back?
?
Слайд 10Find out which stock The Motley Fool’s chief investment officer selected
as the top pick for 2014 in our free report!
